David Wurzer - British Amer Independent Director

BTI Stock  CAD 1.26  1.25  25,100%   

Director

Mr. David M. Wurzer is Independent Director of the Company. He is currently serves as executive vice president and chief investment officer at Connecticut Innovations in Rocky Hill, Conn. Mr. Wurzer is responsible for managing the investment function at CI, which includes staffing, portfolio and risk management, outreach, budget planning and performance measurement. He also is responsible for oversight of the Connecticut Bioscience Innovation Fund and the Regenerative Medicine Research Fund . When Mr. Wurzer joined CI in 2009 as senior managing director of investments, he had extensive seniorlevel experience in operations and finance, including more than 10 years as executive vice president, treasurer and chief financial officer of CuraGen Corporationrationration, a former CI portfolio company. Mr. Wurzer guided the biotech company through its initial public offering and helped raise more than 700 million. Mr. Wurzer was also involved in negotiating strategic and business development alliances with several pharmaceutical and biotech companies, including Roche, Bayer and AmgenFreemont . Mr. Wurzer helped to grow CuraGen and its technology development subsidiary into an operation with more than 500 employees and a market capitalization as high as 5.3 billion. Mr. Wurzer began his professional career with Coopers Lybrand in Hartford, Conn., where he held various accounting and managerial positions. Mr. Wurzer currently serves on the board of directors for several private and public companies, including Standard Diversified Opportunities, Inc., Summit Therapeutics, ReNetX Therapeutics, Natural Polymer Devices, Thetis Pharmaceuticals. His various responsibilities on these boards include lead director, audit committee chair, compensation committee chair, nominating member and audit and compensation committee member. since 2018.
Tenure 6 years
Address 157 Church Street, New Haven, CT, United States, 06510
Phone203 533 7082
Webhttps://www.bioasis.us

British Amer Management Efficiency

The company has return on total asset (ROA) of (0.8058) % which means that it has lost $0.8058 on every $100 spent on assets. This is way below average. British Amer's management efficiency ratios could be used to measure how well British Amer manages its routine affairs as well as how well it operates its assets and liabilities. At this time, British Amer's Return On Capital Employed is fairly stable compared to the past year. Return On Equity is likely to climb to 1.54 in 2024, despite the fact that Return On Tangible Assets are likely to grow to (6.59). At this time, British Amer's Non Current Assets Total are fairly stable compared to the past year. Intangible Assets is likely to climb to about 452.7 K in 2024, whereas Total Current Assets are likely to drop slightly above 711.9 K in 2024.
biOasis Technologies has accumulated 1.9 M in total debt with debt to equity ratio (D/E) of 0.31, which is about average as compared to similar companies. biOasis Technologies has a current ratio of 1.67, which is within standard range for the sector. Debt can assist British Amer until it has trouble settling it off, either with new capital or with free cash flow. So, British Amer's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like biOasis Technologies sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for British to invest in growth at high rates of return. When we think about British Amer's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

DIRECTOR Age

David McAuslandCogeco Communications
65
Stephanie SetiawanQuestor Technology
N/A
Mary LeonLeons Furniture Limited
64
Marc PoulinRichelieu Hardware
52
Mathieu GauvinRichelieu Hardware
N/A
Edgar PangAdvent Wireless
N/A
Paul McFeetersConstellation Software
64
Pierre PomerleauRichelieu Hardware
N/A
Lori ONeillConstellation Software
N/A
Mark CPAConstellation Software
61
Joseph LeonLeons Furniture Limited
59
Carole SalomonCogeco Communications
72
Robert CourteauRichelieu Hardware
N/A
Peter EbyLeons Furniture Limited
79
Lib GibsonCogeco Communications
72
Mark ThimmigiSign Media Solutions
62
Bob MacBeaniSign Media Solutions
N/A
Robert KittelConstellation Software
43
Frank GaglianoLeons Furniture Limited
70
Bruce ReillyiSign Media Solutions
N/A
Joanne FerstmanCogeco Communications
51
Bioasis Technologies Inc., a development stage biopharmaceutical company, engages in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. The company was founded in 2007 and is based in New Haven, Connecticut. British Amer operates under Biotechnology classification in Exotistan and is traded on Commodity Exchange. biOasis Technologies (BTI) is traded on TSX Venture Exchange in Canada and employs 15 people. British Amer is listed under Biotechnology category by Fama And French industry classification.

Management Performance

biOasis Technologies Leadership Team

Elected by the shareholders, the British Amer's board of directors comprises two types of representatives: British Amer inside directors who are chosen from within the company, and outside directors, selected externally and held independent of British. The board's role is to monitor British Amer's management team and ensure that shareholders' interests are well served. British Amer's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, British Amer's outside directors are responsible for providing unbiased perspectives on the board's policies.
David Wurzer, Independent Director
Doug Williams, Executive Vice-President Chief Business Officer
David Jenkins, Chief Officer
Mario Saltarelli, Non-Executive Director
Graeme Dick, Director Relations
Doug MBA, Exec Officer
Christine Antalik, Chief Financial Officer
John Curran, Independent Director
Kim Elton, Director Marketing
Caroline Dircks, Chief Operating Officer
Deborah Rathjen, Executive Chairman of the Board, President, Chief Executive Officer
Aaron Elton, Director Marketing
Mei Tian, VP Research
Dave Jenkins, Chief Officer
B FTSE, CEO Chairman

British Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is British Amer a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for British Stock Analysis

When running British Amer's price analysis, check to measure British Amer's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy British Amer is operating at the current time. Most of British Amer's value examination focuses on studying past and present price action to predict the probability of British Amer's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move British Amer's price. Additionally, you may evaluate how the addition of British Amer to your portfolios can decrease your overall portfolio volatility.